Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants

Press release

Nanoform Finland Plc

September 5, 2024

08:10 a.m. Finnish time / 07:10 a.m. Swedish time

Nanoform and Celanese Expand Collaboration INTO Long-Acting BIOLOGICS DELIVERY THROUGH SMALL IMPLANTS

Helsinki, Finland & Dallas, US – September 5, 2024 - Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Celanese Corporation (“Celanese”), a global specialty materials and chemical company, today announced an expansion of their collaboration to cover biologic drug delivery. The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose^® Drug Delivery platform to further optimize controlled release of biologics from long-acting, therapeutic implants. The collaboration will also include the further development of a long-acting, patient-centric implant for Multiple Sclerosis treatment.

This latest announcement follows promising progress made from an ongoing collaboration, which was first announced in 2023. The companies have combined active pharmaceutical ingredient (API) nanoparticles produced through Nanoform’s controlled expansion of supercritical solutions (CESS^®) technology with the Celanese VitalDose Drug Delivery platform to reduce the burst release of therapeutics from drug-eluting implants, while maintaining high drug load and small implant size. The VitalDose Drug Delivery platform is based on ethylene vinyl acetate (EVA) and offers sustained drug release of small molecules, biologics and RNA for months to years of drug delivery. The platform is tuneable, allowing for customized drug release across a range of form factors and configurations.

"We are pleased to expand our work with Celanese to combine two innovative delivery technologies to create long-acting implants for biologics," said Dr. Edward Haeggström, Nanoform CEO. "These implants have the potential to advance the field of therapeutic development by offering longer-term adherence and potentially better outcomes for patients. Recent data showcases Nanoform's ability to improve drug loading for biologics. Combined with Celanese technology, this has the potential to improve innovator medicines and patients’ lives."

“We are proud to continue our collaboration with Nanoform to combine their particle size control capabilities with our expertise in drug release kinetics,” said Susan Rahe, vice president of pharmaceutical solutions at Celanese. “This strengthens our technology position for controlled-release formulations for biologics and further demonstrates our strategy to embark on innovative partnerships and collaborations that yield patient benefit and create value for our customers.”

In this collaboration both parties carry their own costs of development with the aim to further demonstrate the value of Nanoformed APIs to polymer-based implants both in small and large molecule medicines.

For more information, please visit https://nanoform.com/en/technologies-and-services/small-molecules/ or https://www.vitaldose.com.

For further inquiries, please contact:

Nanoform:

Commercial Inquiries                          Investor Relations                Media Relations

Christian Jones                                  Henri von Haartman            Chris Halling

+44 (0)7804 474771                              +46 (0)768 66 5011              +44 (0)758 041073           

christian.jones@nanoform.com            hvh@nanoform.com               chris.halling@orientation.agency

Celanese:

Investor Relations                               Media Relations – Global      Media Relations Europe (DE)

Bill Cunningham                                    Brian Bianco                            Petra Czugler

+1 972 443 4730                                   +1 972 443 4400                     +49 69 45009 1206

william.cunningham@celanese.com     media@celanese.com           petra.czugler@celanese.com

About Celanese

Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We are committed to sustainability by responsibly managing the materials we create for their entire lifecycle and are growing our portfolio of sustainable products to meet increasing customer and societal demand. We make a positive impact in our communities and prioritize diversity, equity and inclusion across our teams. Celanese is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.

Nanoform Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s

current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2023 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.